Patient, Family Member and Physician Perspectives and Experiences with AML Treatment Decision-Making.

Autor: LeBlanc TW; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, USA., Russell NH; Department of Haematology, Guy's Hospital, London, UK., Hernandez-Aldama L; ArmorUp for LIFE, Philadelphia, USA., Panter C; Adelphi Values Patient-Centered Outcomes, Cheshire, UK. charlotte.panter@adelphivalues.com., Bell TJ; Pfizer Inc., New York, USA., Welch V; Pfizer Inc., New York, USA., Vega DM; Friends of Cancer Research, Washington, DC, USA., O'Hara L; Adelphi Values Patient-Centered Outcomes, Cheshire, UK., Stein J; Adelphi Values Patient-Centered Outcomes, Cheshire, UK., Barclay M; Adelphi Values Patient-Centered Outcomes, Cheshire, UK., Peloquin F; Pfizer Canada ULC, Kirkland, Canada., Brown A; Pfizer Ltd, Tadworth, UK., Healy J; Pfizer Canada ULC, Kirkland, Canada., Morgan L; Adelphi Values Patient-Centered Outcomes, Cheshire, UK., Gater A; Adelphi Values Patient-Centered Outcomes, Cheshire, UK., Hohman R; Friends of Cancer Research, Washington, DC, USA., Amer K; Pfizer Ltd, Tadworth, UK., Maze D; Department of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada., Walter RB; Fred Hutchinson Cancer Research Center, Seattle, USA.
Jazyk: angličtina
Zdroj: Oncology and therapy [Oncol Ther] 2022 Dec; Vol. 10 (2), pp. 421-440. Date of Electronic Publication: 2022 Jun 13.
DOI: 10.1007/s40487-022-00200-9
Abstrakt: Introduction: Treatment decisions in older adults with acute myeloid leukemia (AML) are challenging, particularly for those who are not candidates for intensive chemotherapy (IC), and the trade-offs patients, their families and physicians consider when choosing a treatment option are not well understood. This qualitative research explored the value of extending survival and the treatment decision-making process from a multi-stakeholder perspective.
Methods: Overall, 28 patients with AML (≥ 65 years old, unsuitable for IC), 25 of their relatives and 10 independent physicians from the US, UK and Canada took part in one-on-one, 60-minute qualitative interviews.
Results: Across all stakeholders, improved health-related quality of life (HRQoL), extended survival and relief of AML symptoms were recognized as most important in AML treatment decision-making. However, extending survival in 'good health' was more important than extending survival alone, particularly because of the extra time it gives patients and their relatives together, and allows patients to achieve important goals. Patients' limited understanding of available treatment options, paired with incorrect perceptions of treatment side effects, impacted their involvement in the treatment decision-making process. Patients and physicians perceived physicians to have the most influence in the decision-making process despite their priorities not always aligning.
Conclusion: These findings illustrate the importance of having structured discussions which explicitly assess patients' goals and their understanding and expectations of treatments and also the need for patient friendly resources about the lived experience of AML and available treatment options. These measures will help to ensure that patients are fully involved in the shared decision-making process.
(© 2022. The Author(s).)
Databáze: MEDLINE
Externí odkaz: